| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Luigi Maione, Cristina Albrici, Solange Grunenwald, Céline Mouly, Vincenzo Cimino, Anne-Lise Lecoq, Jean Claude Souberbielle, Philippe Caron, Philippe Chanso. IGF-I variability over repeated measures in patients with acromegaly under long-acting somatostatin receptor ligands. The Journal of clinical endocrinology and metabolism. 2022-06-30. PMID:35772775. |
igf-i variability over repeated measures in patients with acromegaly under long-acting somatostatin receptor ligands. |
2022-06-30 |
2023-08-14 |
Not clear |
| Luigi Maione, Cristina Albrici, Solange Grunenwald, Céline Mouly, Vincenzo Cimino, Anne-Lise Lecoq, Jean Claude Souberbielle, Philippe Caron, Philippe Chanso. IGF-I variability over repeated measures in patients with acromegaly under long-acting somatostatin receptor ligands. The Journal of clinical endocrinology and metabolism. 2022-06-30. PMID:35772775. |
in patients with acromegaly on long-term treatment with long-acting somatostatin receptor ligands (srls), the time of blood collection for igf-i measurement after injection is not well defined. |
2022-06-30 |
2023-08-14 |
Not clear |
| Alessandro Brunetti, Simone Antonini, Andrea Saladino, Elisabetta Lavezzi, Benedetta Zampetti, Renato Cozz. Clinical Management of Acromegaly: Therapeutic Frontiers and New Perspectives for Somatostatin Receptor Ligands (SRLs). Medicina (Kaunas, Lithuania). vol 58. issue 6. 2022-06-24. PMID:35744057. |
clinical management of acromegaly: therapeutic frontiers and new perspectives for somatostatin receptor ligands (srls). |
2022-06-24 |
2023-08-14 |
Not clear |
| Alessandro Brunetti, Simone Antonini, Andrea Saladino, Elisabetta Lavezzi, Benedetta Zampetti, Renato Cozz. Clinical Management of Acromegaly: Therapeutic Frontiers and New Perspectives for Somatostatin Receptor Ligands (SRLs). Medicina (Kaunas, Lithuania). vol 58. issue 6. 2022-06-24. PMID:35744057. |
somatostatin receptor ligands (srls) represent a true milestone in the medical therapy for acromegaly. |
2022-06-24 |
2023-08-14 |
Not clear |
| C Bona, N Prencipe, A M Berton, F Bioletto, M Parasiliti-Caprino, V Gasco, E Ghigo, S Grottol. Mean GH profile is more accurate than single fasting GH in the evaluation of acromegaly disease control during somatostatin receptor ligands therapy. Journal of endocrinological investigation. 2022-06-24. PMID:35748978. |
mean gh profile is more accurate than single fasting gh in the evaluation of acromegaly disease control during somatostatin receptor ligands therapy. |
2022-06-24 |
2023-08-14 |
Not clear |
| C Bona, N Prencipe, A M Berton, F Bioletto, M Parasiliti-Caprino, V Gasco, E Ghigo, S Grottol. Mean GH profile is more accurate than single fasting GH in the evaluation of acromegaly disease control during somatostatin receptor ligands therapy. Journal of endocrinological investigation. 2022-06-24. PMID:35748978. |
this study aims to compare the accuracy of mean gh profile (ghp) < 2.5 ng/ml and single fasting gh (sgh) < 1 ng/ml in the evaluation of disease control in acromegaly patients during somatostatin receptor ligands (srls) therapy. |
2022-06-24 |
2023-08-14 |
Not clear |
| Atsushi Ishida, Hiroki Shichi, Hidenori Fukuoka, Hideki Shiramizu, Naoko Inoshita, Shozo Yamad. Temozolomide and Capecitabine Treatment for an Aggressive Somatotroph Pituitary Tumor: A Case Report and Literature Review. Frontiers in oncology. vol 12. 2022-06-17. PMID:35712496. |
aggressive somatotroph pituitary tumor that causes acromegaly is extremely rare and resists conventional treatments such as multiple surgeries, radiotherapies, and various types of somatostatin analogs. |
2022-06-17 |
2023-08-14 |
Not clear |
| Beata Rak-Makowska, Bernard Khoo, Piya Sen Gupta, P Nicholas Plowman, Ashley B Grossman, Márta Korbonit. Ockham's Razor for a Retinal Lesion and Acromegaly and Breaking the Vicious Circle. Journal of the Endocrine Society. vol 6. issue 7. 2022-06-15. PMID:35702603. |
treatment consists of surgical removal of the primary tumor, cytostatic therapy, "cold" or radioactive somatostatin analogue treatment, and medical therapy for acromegaly, if needed. |
2022-06-15 |
2023-08-14 |
Not clear |
| Beata Rak-Makowska, Bernard Khoo, Piya Sen Gupta, P Nicholas Plowman, Ashley B Grossman, Márta Korbonit. Ockham's Razor for a Retinal Lesion and Acromegaly and Breaking the Vicious Circle. Journal of the Endocrine Society. vol 6. issue 7. 2022-06-15. PMID:35702603. |
cold and radioactive somatostatin analogue therapy reduced both ghrh and insulin-like growth factor 1 (igf-1) levels, but normalization of the biochemical markers of acromegaly was only achieved after pegvisomant was introduced. |
2022-06-15 |
2023-08-14 |
Not clear |
| Joan Gil, Montserrat Marques-Pamies, Miguel Sampedro, Susan M Webb, Guillermo Serra, Isabel Salinas, Alberto Blanco, Elena Valassi, Cristina Carrato, Antonio Picó, Araceli García-Martínez, Luciana Martel-Duguech, Teresa Sardon, Andreu Simó-Servat, Betina Biagetti, Carles Villabona, Rosa Cámara, Carmen Fajardo-Montañana, Cristina Álvarez-Escolá, Cristina Lamas, Clara V Alvarez, Ignacio Bernabéu, Mónica Marazuela, Mireia Jordà, Manel Puig-Doming. Data mining analyses for precision medicine in acromegaly: a proof of concept. Scientific reports. vol 12. issue 1. 2022-06-01. PMID:35643771. |
predicting which acromegaly patients could benefit from somatostatin receptor ligands (srl) is a must for personalized medicine. |
2022-06-01 |
2023-08-13 |
Not clear |
| Emre Gezer, Yeliz Demirhan, Alev Selek, Zeynep Cantürk, Berrin Çetinarslan, Mehmet Sözen, Damla Köksalan, Ayfer Peker Karatopra. Comparison between somatostatin analog injections. Revista da Associacao Medica Brasileira (1992). vol 68. issue 4. 2022-06-01. PMID:35649076. |
long-acting depot formulations of somatostatin analogs, i.e., octreotide and lanreotide, are the first-line medical therapies for patients with acromegaly to whom surgery/radiotherapy cannot be performed or who have inadequate response. |
2022-06-01 |
2023-08-13 |
Not clear |
| Emre Gezer, Yeliz Demirhan, Alev Selek, Zeynep Cantürk, Berrin Çetinarslan, Mehmet Sözen, Damla Köksalan, Ayfer Peker Karatopra. Comparison between somatostatin analog injections. Revista da Associacao Medica Brasileira (1992). vol 68. issue 4. 2022-06-01. PMID:35649076. |
in this study, we aimed to evaluate the short-term local and systemic adverse reactions developed after the somatostatin analogs injections in the patients with acromegaly, in order to compare the side effects of somatostatin analogs injections. |
2022-06-01 |
2023-08-13 |
Not clear |
| Muhammed Kizilgul, Hakan Duger, Narin Imga Nasiroglu, Erkam Sencar, Sema Hepsen, Pinar Akhanli, Dilek Berker, Erman Cakal, Hayri Bostan, Bekir Uca. Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature. Archives of endocrinology and metabolism. 2022-05-25. PMID:35612842. |
efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature. |
2022-05-25 |
2023-08-13 |
Not clear |
| Muhammed Kizilgul, Hakan Duger, Narin Imga Nasiroglu, Erkam Sencar, Sema Hepsen, Pinar Akhanli, Dilek Berker, Erman Cakal, Hayri Bostan, Bekir Uca. Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature. Archives of endocrinology and metabolism. 2022-05-25. PMID:35612842. |
it is reported that adding cabergoline to somatostatin analog (ssa) normalizes igf-1 levels approximately in one-third of patients with acromegaly. |
2022-05-25 |
2023-08-13 |
Not clear |
| Avital Beig, Rose Ackermann, Yan Wang, Richard Schutzman, Steven P Schwendema. Minimizing the initial burst of octreotide acetate based long-acting microspheres by the solvent evaporation method. International journal of pharmaceutics. 2022-05-24. PMID:35609832. |
sandostatin long-acting release (slar) depot for 1-month controlled release of octreotide is a somatostatin analogue product that has been used extensively in the pharmacological treatment of acromegaly. |
2022-05-24 |
2023-08-13 |
rat |
| Kevin C J Yuen, Susan L Samso. Oral Octreotide: A Review of Recent Clinical Trials and Practical Recommendations for Its Use in the Treatment of Patients With Acromegaly. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2022-04-22. PMID:35452815. |
oral octreotide capsules (ooc) that combine octreotide with a transient permeability enhancer technology are the first oral somatostatin receptor ligand (srl) approved in the us for acromegaly. |
2022-04-22 |
2023-08-13 |
Not clear |
| Cem Sulu, Ayyüce Begüm Bektaş, Serdar Şahin, Emre Durcan, Zehra Kara, Ahmet Numan Demir, Hande Mefkure Özkaya, Necmettin Tanrıöver, Nil Çomunoğlu, Osman Kızılkılıç, Nurperi Gazioğlu, Mehmet Gönen, Pınar Kadıoğl. Machine learning as a clinical decision support tool for patients with acromegaly. Pituitary. 2022-04-18. PMID:35435565. |
to develop machine learning (ml) models that predict postoperative remission, remission at last visit, and resistance to somatostatin receptor ligands (srl) in patients with acromegaly and to determine the clinical features associated with the prognosis. |
2022-04-18 |
2023-08-13 |
Not clear |
| Na Yu, Linjie Wang, Hongbo Yang, Hui Pan, Lian Duan, Huijuan Zh. Persistent remission of acromegaly in a patient with GH-secreting pituitary adenoma: Effect of treatment with pasireotide long-acting release and consequence of treatment withdrawal. Journal of clinical pharmacy and therapeutics. 2022-02-15. PMID:35167717. |
somatostatin analogues (ssas) have been used for the treatment of acromegaly for several decades. |
2022-02-15 |
2023-08-13 |
Not clear |
| Eva C Coopmans, Aart J van der Lely, Sebastian J C M M Negger. Approach to the patient with treatment resistant acromegaly. The Journal of clinical endocrinology and metabolism. 2022-01-28. PMID:35090028. |
although most tumors in patients with acromegaly are benign and are cured or controlled by surgery and/or first-generation somatostatin receptor ligands therapy, some can behave more aggressively and are resistant to these standard therapies. |
2022-01-28 |
2023-08-13 |
Not clear |
| E Vitali, E Palagano, M L Schiavone, G Mantovani, C Sobacchi, G Mazziotti, A Lani. Direct effects of octreotide on osteoblast cell proliferation and function. Journal of endocrinological investigation. 2022-01-12. PMID:35020172. |
octreotide (oct) is a first-generation somatostatin analog (ssa) used in the treatment of acromegaly and neuroendocrine tumors (nets). |
2022-01-12 |
2023-08-13 |
Not clear |